King's College London

Research portal

Minimising menopausal side effects whilst treating endometriosis and fibroids

Research output: Contribution to journalArticle

Standard

Minimising menopausal side effects whilst treating endometriosis and fibroids. / Simpson, Paul D.; McLaren, James S.; Rymer, Janice; Morris, Edward P.

In: Post reproductive health, Vol. 21, No. 1, 01.03.2015, p. 16-23.

Research output: Contribution to journalArticle

Harvard

Simpson, PD, McLaren, JS, Rymer, J & Morris, EP 2015, 'Minimising menopausal side effects whilst treating endometriosis and fibroids', Post reproductive health, vol. 21, no. 1, pp. 16-23. https://doi.org/10.1177/2053369114568440

APA

Simpson, P. D., McLaren, J. S., Rymer, J., & Morris, E. P. (2015). Minimising menopausal side effects whilst treating endometriosis and fibroids. Post reproductive health, 21(1), 16-23. https://doi.org/10.1177/2053369114568440

Vancouver

Simpson PD, McLaren JS, Rymer J, Morris EP. Minimising menopausal side effects whilst treating endometriosis and fibroids. Post reproductive health. 2015 Mar 1;21(1):16-23. https://doi.org/10.1177/2053369114568440

Author

Simpson, Paul D. ; McLaren, James S. ; Rymer, Janice ; Morris, Edward P. / Minimising menopausal side effects whilst treating endometriosis and fibroids. In: Post reproductive health. 2015 ; Vol. 21, No. 1. pp. 16-23.

Bibtex Download

@article{61f6ba45162342cf9e45e84f16ac0a06,
title = "Minimising menopausal side effects whilst treating endometriosis and fibroids",
abstract = "Medical management of endometriosis and fibroids involves manipulation of the hypothalamic-pituitary-gonadal axis to alter the balance of sex hormones thereby inhibiting disease progression and ameliorate symptoms. Unfortunately, resultant menopausal symptoms sometimes limit the tolerability and duration of such treatment. The use of gonadotrophin-releasing hormone agonists to treat these diseases can result in short-term hypoestrogenic and vasomotor side effects as well as long-term impacts on bone health and cardiovascular risk. The routine use of add-back hormone replacement has reduced these risks and increased patient compliance, making this group of drugs more useful as a medium-term treatment option. The estrogen threshold hypothesis highlights the concept of a 'therapeutic window' in which bone loss is minimal but the primary disease is not aggravated. It explains why add-back therapy is appropriate for such patients and helps to explain the basis behind new developments in the treatment of hormonally responsive gynaecological conditions such as gonadotrophin-releasing hormone antagonists and progesterone receptor modulators.",
keywords = "Add-back, endometriosis, fibroids, GnRHantagonists, SPRMs",
author = "Simpson, {Paul D.} and McLaren, {James S.} and Janice Rymer and Morris, {Edward P.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1177/2053369114568440",
language = "English",
volume = "21",
pages = "16--23",
journal = "Post reproductive health",
issn = "2053-3691",
publisher = "Sage Publications",
number = "1",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Minimising menopausal side effects whilst treating endometriosis and fibroids

AU - Simpson, Paul D.

AU - McLaren, James S.

AU - Rymer, Janice

AU - Morris, Edward P.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Medical management of endometriosis and fibroids involves manipulation of the hypothalamic-pituitary-gonadal axis to alter the balance of sex hormones thereby inhibiting disease progression and ameliorate symptoms. Unfortunately, resultant menopausal symptoms sometimes limit the tolerability and duration of such treatment. The use of gonadotrophin-releasing hormone agonists to treat these diseases can result in short-term hypoestrogenic and vasomotor side effects as well as long-term impacts on bone health and cardiovascular risk. The routine use of add-back hormone replacement has reduced these risks and increased patient compliance, making this group of drugs more useful as a medium-term treatment option. The estrogen threshold hypothesis highlights the concept of a 'therapeutic window' in which bone loss is minimal but the primary disease is not aggravated. It explains why add-back therapy is appropriate for such patients and helps to explain the basis behind new developments in the treatment of hormonally responsive gynaecological conditions such as gonadotrophin-releasing hormone antagonists and progesterone receptor modulators.

AB - Medical management of endometriosis and fibroids involves manipulation of the hypothalamic-pituitary-gonadal axis to alter the balance of sex hormones thereby inhibiting disease progression and ameliorate symptoms. Unfortunately, resultant menopausal symptoms sometimes limit the tolerability and duration of such treatment. The use of gonadotrophin-releasing hormone agonists to treat these diseases can result in short-term hypoestrogenic and vasomotor side effects as well as long-term impacts on bone health and cardiovascular risk. The routine use of add-back hormone replacement has reduced these risks and increased patient compliance, making this group of drugs more useful as a medium-term treatment option. The estrogen threshold hypothesis highlights the concept of a 'therapeutic window' in which bone loss is minimal but the primary disease is not aggravated. It explains why add-back therapy is appropriate for such patients and helps to explain the basis behind new developments in the treatment of hormonally responsive gynaecological conditions such as gonadotrophin-releasing hormone antagonists and progesterone receptor modulators.

KW - Add-back

KW - endometriosis

KW - fibroids

KW - GnRHantagonists

KW - SPRMs

UR - http://www.scopus.com/inward/record.url?scp=84945457318&partnerID=8YFLogxK

U2 - 10.1177/2053369114568440

DO - 10.1177/2053369114568440

M3 - Article

C2 - 25802141

AN - SCOPUS:84945457318

VL - 21

SP - 16

EP - 23

JO - Post reproductive health

JF - Post reproductive health

SN - 2053-3691

IS - 1

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454